# Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

> **NCT03088813** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 491 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Irinotecan liposome injection
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT03088813
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-25
- **Primary completion:** 2022-02-08
- **Final completion:** 2023-07-27
- **Target enrollment:** 491 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088813, "Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03088813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*